Table 1.
Studied formulations of PGS/gelatine nanoparticles loaded with sunitinib malate
| Code | Sebacic acid/glycerol | Gelatine/PGS | Drug/carrier, % | Particle size ±SD, nm | PDI | Zeta potential, mV | EE% | RE150 % |
|---|---|---|---|---|---|---|---|---|
| S1 G6.5 D20 | 1 | 6.5 | 20 | 484.3 ± 12.8 | 0.3 ± 0.1 | 6.8 | 42.6 ± 0.1 | 22.2 ± 3.9 |
| S1 G6.5 D20 | 1 | 6.5 | 20 | 479.6 ± 54.8 | 0.4 ± 0.3 | 9.8 | 42.2 ± 0.0 | 21.3 ± 2.2 |
| S1 G3 D10 | 1 | 3 | 10 | 446.6 ± 38.8 | 0.5 ± 0.1 | 6.7 | 20.5 ± 0.0 | 35.8 ± 2.5 |
| S1 G6.5 D20 | 1 | 6.5 | 20 | 230.3 ± 3.5 | 0.5 ± 0.1 | 8.1 | 43.8 ± 0.1 | 19.8 ± 2.7 |
| S2 G6.5 D30 | 2 | 6.5 | 30 | 340.7 ± 53.7 | 0.5 ± 0.1 | 20.1 | 21.5 ± 0.2 | 28.9 ± 4.8 |
| S1 G6.5 D20 | 1 | 6.5 | 20 | 231.7 ± 21.2 | 0.5 ± 0.1 | 2.3 | 42.1 ± 1.1 | 18.9 ± 2.5 |
| S1 G10 D10 | 1 | 10 | 10 | 270.3 ± 29.1 | 0.5 ± 0.1 | 7.9 | 20.6 ± 1.6 | 25.1 ± 0.9 |
| S2 G3 D20 | 2 | 3 | 20 | 418.3 ± 0.5 | 0.3 ± 0.2 | 14.7 | 25.3 ± 0.1 | 17.2 ± 1.1 |
| S0.5 G10 D20 | 0.5 | 10 | 20 | 247.7 ± 5.1 | 0.4 ± 0.1 | 9.6 | 17.5 ± 0.1 | 81.2 ± 3.4 |
| S1 G10 D30 | 1 | 10 | 30 | 268.3 ± 17.2 | 0.5 ± 0.2 | 14.9 | 23.8 ± 0.3 | 25.9 ± 1.7 |
| S2 G6.5 D10 | 2 | 6.5 | 10 | 412.6 ± 16.7 | 0.3 ± 0.1 | 14.1 | 19.1 ± 0.3 | 45.7 ± 1.6 |
| S1 G3 D30 | 1 | 3 | 30 | 472.3 ± 6.8 | 0.4 ± 0.1 | 9.6 | 36.3 ± 1.0 | 12.8 ± 1.6 |
| S2 G10 D20 | 2 | 10 | 20 | 319.3 ± 10.9 | 0.4 ± 0.1 | 8.9 | 22.3 ± 1.2 | 55.7 ± 5.9 |
| S0.5 G3 D20 | 0.5 | 3 | 20 | 379.3 ± 18.9 | 0.5 ± 0.1 | 10.3 | 27.8 ± 0.1 | 30.5 ± 2.0 |
| S0.5 G6.5 D30 | 0.5 | 6.5 | 30 | 250.7 ± 40.1 | 0.5 ± 0.1 | 11.3 | 28.1 ± 0.3 | 63.5 ± 3.1 |
| S0.5 G6.5 D10 | 0.5 | 6.5 | 10 | 350.7 ± 3.9 | 0.3 ± 0.2 | 15.3 | 24.9 ± 0.4 | 92.5 ± 2.8 |
| S1 G6.5 D20 | 1 | 6.5 | 20 | 305.3 ± 7.1 | 0.4 ± 0.1 | 5.9 | 41.7 ± 1.8 | 22.5 ± 2.8 |